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ABSTRACT
Comorbidity is common in patients with chronic obstructive pulmonary disease (COPD); however, the relationship 
between comorbidity and quality of life is inconsistent. The objective was to establish the prevalence of comorbidity 
and the relationship with the quality of life of patients with COPD in Santa Marta, Colombia. A cross-sectional 
study was designed in which outpatients diagnosed with COPD participated. Quality of life was evaluated with the 
CAT (COPD Assessment Test) instrument; scores higher than ten were considered poor quality of life. The sample 
was of 292 patients, in ages between 49 and 95 years; 61.6% male. A group of 232 participants (79.5%) presented 
some comorbidity associated with COPD. Quality of life was reduced in 192 patients (65.8%). Comorbidity did not 
significantly add to the quality of life (OR = 1.33. 95% CI 0.72-2.45), adjusted for age and sex. It is concluded that 
comorbidity is very frequent; however, it does not affect the quality of life in patients with COPD in Santa Marta. 
More research is needed with more participants.
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RESUMEN
La comorbilidad es frecuente en pacientes con enfermedad pulmonar obstructiva crónica (EPOC); sin embargo, 
es inconsistente la relación entre la comorbilidad y la calidad de vida. El objetivo fue establecer la prevalencia de 
comorbilidad y la relación con la calidad de vida de los pacientes con EPOC en Santa Marta, Colombia. Se diseñó 
un estudio transversal en el que participaron pacientes ambulatorios con diagnóstico de EPOC. La calidad de vida 
se evaluó con el instrumento CAT (COPD Assessment Test), las puntuaciones mayores de diez se consideraron 
pobre calidad de vida. La muestra fue de 292 pacientes, en edades entre 49 y 95 años; 61,6% de sexo masculino. 
Un grupo de 232 participantes (79,5%) presentó alguna comorbilidad asociada a la EPOC. La calidad de vida 
fue pobre en 192 pacientes (65,8%). La comorbilidad no asoció significativamente a la calidad de vida (OR=1,33; 
IC95% 0,72-2,45), ajustado por edad y sexo. Se concluye que la comorbilidad es muy frecuente; no obstante, afecta 
poco la calidad de vida en pacientes con EPOC de Santa Marta. Se necesitan más investigaciones con mayor 
número de participantes.
Palabras clave: enfermedad pulmonar obstructiva crónica; Comorbilidad; Calidad de vida; Estudios transversales.
INTRODUCTION
In Colombia, the prevalence of chronic obstruc-tive pulmonary disease (COPD) is around 
10%1. COPD is characterized by decreased air-
flow and inflammatory response and manifests 
clinically with dyspnea, cough, and expectora-
tion, of chronic course with remissions partial 
and exacerbations2.
Comorbidity is understood as the coexistence of 
diseases or the appearance of an additional con-
dition in a person with a previous diagnosis3-5. 
The presence of comorbidity frequently deterio-
rates the course of concurrent diseases, under-
mines the quality of life and usually increases 
the morbidity and mortality of these patients6-8.
Quality of life is a concept under permanent 
construction, without a consensus on it; never-
theless, it can be defined in a simple way as the 
perception or general feeling of emotional, phys-
ical and social well-being9,10. Given the clinical 
characteristics of COPD, patients present with 
high frequency a significant deterioration in the 
quality of life, that is, a considerable limitation in 
the activities of daily life or work demands11-13.
The prevalence of comorbidity in patients with 
COPD varies according to the characteristics of 
the population and the number of concurrent 
diseases evaluated. Crisafulli et al14 reported that 
51% of patients who presented at least one con-
dition concomitant with COPD. And García-
Olmos observed that 91% of patients with 
COPD reported a comorbidity15.
About comorbid conditions, Battaglia et al16 
observed that the most frequent comorbidities 
were hypertension (64.7%), diabetes (28.5%), 
coronary disease (19.9%), cardiac arrhythmia 
(16.6%), and congestive heart failure (3.8%). 
And Pucha et al17 documented that the most 
common associated entities were incontinence 
or prostatic disease (63.6%), arthritis (58.6%), 
depressive symptoms (42.5%), coronary heart 
disease (23.4%), chronic kidney disease (21.7%), 
congestive heart failure (15.1%) and diabetes 
(13.9%).
Regarding the association between comorbid-
ity and quality of life in patients with COPD, 
the findings are contradictory. On the one hand, 
Battaglia et al16 did not observe a statistically sig-
nificant association and, on the other hand, Pucha 
et al17 found that only some conditions (conges-
tive heart failure, arthritis, diabetes, and inconti-
nence or prostatic disease) showed deterioration 
in quality of life in the presence of comorbidity
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These observations and others suggest that the 
relationship between comorbidity and quality of 
life in patients with COPD is complex and that 
the multiple particular mediating factors associ-
ated with COPD and specific comorbidity inter-
act in a singular way16-20. In the present inves-
tigation, general comorbidity was also taken, 
without discriminating by diagnosis, to present 
the association between comorbidity and qual-
ity of life in COPD, a fact that was omitted in 
previous investigations16,17. This knowledge 
will undoubtedly contribute to rethinking the 
importance of comorbidities in the evaluation 
and follow-up of patients with COPD2,4.
The study aimed to quantify the association 
between comorbidity and quality of life in out-
patients with COPD in Santa Marta, Colombia.
MATERIALS AND METHODS
Design
A quantitative study of observational type was 
designed given that no interventions were car-
ried out. The prevalence of an event was ana-
lyzed cross-sectionally and associations were 
established.
Population and sample
We requested the participation of patients with 
COPD treated in different public and private 
institutions of Santa Marta; a city located in 
the Colombian Caribbean at sea level. A non-
probabilistic sample was taken, for convenience, 
consecutively. However, it was expected to have 
at least 250 patients that allowed the calculation 
of associations with sufficiently narrow confi-
dence intervals21. Only those patients attended 
in specialized outpatient services, regardless 
of another characteristic, during the year 2016 
were included. Patients who did not complete 
the entire evaluation were excluded.
Procedure and measurements
The patients were evaluated in the outpatient 
consultation by one of the investigators (JCPP). 
During the evaluation, the primary demographic 
data, the comorbidity informed and the quality 
of life were quantified. The COPD Assessment 
Test (CAT) measured the quality.
The diagnosis of COPD was confirmed by clini-
cal evaluation and the history of exposure to 
the cigarette or particulate material, that is, 
the presence of dyspnea, cough and sputum 
production in people with lung function com-
patible with COPD, by the GOLD guidelines 
(Global Initiative for Chronic Obstructive Lung 
Disease)22.
Spirometries were performed with the spirometer 
(Master Screen PFT System of CareFusion-EU). 
The criteria and procedures for the measure-
ment were selected according to the recommen-
dations of ATS / ERS for the standardization of 
spirometry23,24.
The CAT is an instrument that was exclu-
sively designed to measure the quality of life 
of people with COPD and it includes a set of 
eight items that qualify cough severity, expul-
sion of phlegm, chest tightness, shortness 
of breath during the effort, ease to perform 
domestic activities, feeling of safety when leav-
ing home, quality of sleep and energy level. 
Each item gives six response options to which 
are assigned from zero to five points, from 
lowest to highest severity. Consequently, the 
total scores are between zero and 40. Scores 
higher than 10 indicate significant deteriora-
tion or reduced quality of life. For the pres-
ent study, little deterioration in the quality of 
life was considered to have lower scores 10 
and high deterioration, higher than 1025. This 
scale has shown excellent internal consistency 
in studies in populations of other countries 
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around the world26. Given that the perfor-
mance of the instrument before the analysis 
was unknown, it was calculated in the sample 
that participated in the study that Cronbach’s 
alpha is described, which is a quick and simple 
measure of validity and reliability, the CAT 
showed alpha of 0.71.
Statistic analysis
The descriptive analysis was limited to the deter-
mination of frequencies and percentages (%) for 
nominal and mean data and standard devia-
tion (SD) for quantitative data. Additionally, the 
age of the patients was dichotomized into two 
categories (minors and older than 75 years). 
We calculated risk opportunities or reasons for 
disparity (OR) with 95% confidence intervals 
(95% CI). Finally, the association was adjusted 
by age (two categories) and by sex. The analysis 
was performed with the statistical package IBM-
SPSS Statistics, version 2227.
Declaration on ethical aspects
It was reviewed and approved by an ethics board. 
The participants signed informed consent once 
they knew the objectives of the study and that 
the participation did not represent a higher 
risk for physical and emotional integrity than 
the routine clinical review for COPD, all fol-
lowing Resolution 8430 of 1993 of the Ministry 
of Health28.
RESULTS
A total of 292 patients made up the study sample. 
The ages of the participants were observed in 
ages between 49 and 95 years, (M = 73.5, SD = 
8.7). Those younger than 75 years old were 162 
patients (55.5%) and those older than 75 years, 
130 (44.5%). According to sex, the distribution 
was: 180 men (61.6%) and 112 women (38.4%).
A group of 232 patients (79.5%) presented some 
comorbidity associated with COPD. Table 1 
shows the observed comorbidities. The CAT 
showed scores between 0 and 38, with an average 
of 14.4 points (SD = 8.1). According to the cut-
off point of 10, the quality of life was poor in 192 
patients (65.8%) and acceptable in 100 (34.2%).
The crude association between comorbidity and 
quality of life showed value OR = 1.78 (95% CI 
0.99-3.18) and OR = 1.33 (95% CI 0.72-2.45) 
once adjusted for age and sex. The crude and 
adjusted associations for comorbidities with 
prevalence greater than 5% presented in Table 2 
showed the same pattern.
Table 1. Comorbidities in patients with COPD in Santa Marta, Colombia.
Comorbidity f %
Arterial hypertension 154 52.7
Osteoporosis 41 14.0
Mellitus Diabetes 30 10.3
Coronary heart disease 27 9.2
Bronchial asthma 27 9.2
Gastroesophageal reflux disease 21 7.2
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Comorbidity f %
Pulmonary tuberculosis or sequelae 18 6.2
Depressive disorder 17 5.8
Congestive heart failure 17 5.8
Bronchogenic cancer 13 4.5
Bronchiectasis 13 4.5
Asthma / COPD overlap syndrome 13 4.5
Pulmonary hypertension and right heart failure 12 4.1
Stroke 8 2.7
Pulmonary fibrosis of any etiology 8 2.7
Cardiac arrhythmias (atrial fibrillation) 7 2.4
Obstructive sleep apnea/hypopnea syndrome 7 2.4
Hypothyroidism 6 2.1
Chronic renal failure 5 1.7
Other 51 17.5
Table 2. Crude and adjusted associations for the most frequent comorbidities.
Comorbidity OR (95% CI)Crude*
OR (95% CI)
Adjusted*
Arterial hypertension 1.26 (0.74-2.04) 0.99 (0.59-1.67)
Osteoporosis 2.02 (0.92-4.42) 1.38 (0.59-3.18)
Mellitus Diabetes 0.89 (0.41-1.95) 0.82 (0.36-1.84)
Coronary heart disease 0.87 (0.38-1.99) 0.99 (0.43-3.31)
Bronchial asthma 1.92 (0.75-4.93) 2.32 (0.88-6.13)
Gastroesophageal reflux disease 3.34 (0.96-11.64) 3.25 (0.92-11.51)
Pulmonary tuberculosis or sequelae 1.04 (0.38-2.87) 1.22 (0.43-3.45)
Depressive disorder 1.74 (0.55-5.49) 2.03 (0.63-6.61)
Congestive heart failure 2.54 (0.71-9.07) 2.67 (0.73-9.74)
* By age and sex
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DISCUSSION
In the present investigation, it is observed that 
approximately 80% of patients report some 
comorbidity and about 66% have a poor qual-
ity of life. These variables were completely 
independent.
The prevalence of comorbidity observed in 
the present investigation is in the range of that 
reported in previous studies that documented 
prevalence between 50 and 90 of patients suf-
fering from COPD14,15. Comorbidity is the rule 
in patients with COPD; however, the frequency 
varies according to the characteristics of the 
populations examined29.
In the same way, it was observed in the present 
analysis that the quality of life of patients with 
COPD is independent of the associated comor-
bidity. This observation is consistent with the 
findings of Battaglia et al16 who reported that 
cardiac arrhythmia comorbidities, diabetes, 
coronary heart disease, hypertension, conges-
tive heart failure and major depressive disor-
der did not significantly impair the quality of 
life of Italian patients. However, this observa-
tion diverges substantially from the measure-
ments made by Putcha et al17 that showed that 
some comorbidities negatively affected the 
quality of life in a group of American patients. 
Undoubtedly, the association is marked by phys-
iological changes, without forgetting the social 
and cultural aspects that modify the course of 
any illness, which add comorbidity to the pul-
monary function of patients with COPD8,30.
The evaluation of comorbidity in patients with 
COPD is essential not only in therapeutic plans 
and actions aimed at comprehensive rehabilita-
tion but can also help to estimate the impact on 
quality of life, according to the nature of comor-
bidity. It is evident that some comorbidities, for 
example, congestive heart failure, can signifi-
cantly deteriorate the symptoms of COPD and 
the overall performance of patients11,14,31.
This study provides new knowledge about the 
association between general comorbidity and 
quality of life in a group of COPD patients living 
at sea level. However, it has the inherent limi-
tations of transversal analytical studies that do 
not allow to know with complete certainty the 
direction of the association32. An additional bar-
rier is represented by the heterogeneous nature 
of the diseases considered for the comorbidity 
category, without considering the physiological 
aspects that explain the association. And finally, 
the size of the sample for the calculation of the 
association for comorbidities with low preva-
lence should be considered small33.
As a conclusion, comorbidity is present in four 
out of five and the significant deterioration in the 
quality of life of two out of every three patients 
with COPD in Santa Marta, Colombia. However, 
quality of life is independent of comorbidity. 
New research is needed to quantify this relation-
ship in a larger sample of patients with specific 
comorbidities.
DECLARATION ON CONFLICT OF 
INTEREST
The authors have no conflicts of interest to 
express.
BIBLIOGRAPHIC REFERENCES
1. Caballero A, Torres-Duque CA, Jaramillo C, 
Bolívar F, Sanabria F, Osorio P, et al. Prevalence 
of COPD in five Colombian cities situated at 
low, medium, and high altitude (PREPOCOL 
study). Chest. 2008; 133 (2): 343-9. DOI 10.1378/
chest.07-1361.
John Carlos Pedrozo-Pupo, Adalberto Campo-Arias, Héctor De La Torre
279Duazary: Revista Internacional de Ciencias de la Salud / ISSN: 1794-5992 / Vol. 15, No. 3, septiembre - diciembre de 2018
DOI: http://dx.doi.org/10.21676/2389783X.2418
2. Nici L, Donner C, Wouters E, Zuwallack R, 
Ambrosino N, Bourbeau J, et al. American 
Thoracic Society/European Respiratory Society 
statement on pulmonary rehabilitation.  Am J 
Respir Crit Care Med. 2006; 173 (12): 1390-413. 
DOI: 10.1164/rccm.200508-1211ST
3. de Groot V, Beckerman H, Lankhorst GJ, 
Bouter LM. How to measure comorbidity: a 
critical review of available methods.  J Clin 
Epidemiol. 2003; 56 (3): 221-9.
4. Bonavita V, De Simone R. Towards a definition 
of comorbidity in the light of clinical 
complexity.  Neurol Sci. 2008;  29: 99-102. DOI 
10.1007/s10072-008-0898-1
5. Dean E. Multiple morbidities assessment.  Nurs 
Stand. 2017;  31 (34): 15. DOI 10.7748/
ns.31.34.15.s16
6. Sin DD, Man SP. Chronic obstructive pulmonary 
disease as a risk factor for cardiovascular morbidity 
and mortality. Proc Am Thorac Soc. 2005; 2 (1): 
8-11. DOI 10.1513/pats.200404-032MS
7. Divo M, Cote C, de Torres JP, Casanova C, 
Marin JM, Pinto-Plata V, et al. Comorbidities 
and risk of mortality in patients with chronic 
obstructive pulmonary disease. Am J Respir Crit 
Care Med. 2012; 186 (2): 155-161. DOI 10.1164/
rccm.201201-0034OC
8. Decramer M, Janssens W. Chronic obstructive 
pulmonary disease and comorbidities.  Lancet 
Respir Med. 2013;  1(1):73-83. DOI 10.1016/
S2213-2600(12)70060-7
9. Ardila R. Calidad de vida: una definición 
integradora. Rev Latinoam Psicol. 2003; 35 (2): 
161-4.
10. Urzúa A, Caqueo-Urízar A. Calidad de 
vida: Una revisión teórica del concepto.  Ter 
Psicol. 2012;  30: 61-71. DOI 10.4067/
S0718-48082012000100006
11. Niewoehner DE. The impact of severe 
exacerbations on quality of life and the clinical 
course of chronic obstructive pulmonary disease. 
Am J Med. 2006; 119; 10 (Suppl. 1): 38-45. DOI 
10.1016/j.amjmed.2006.08.006
12. Monteagudo M, Rodríguez-Blanco T, Llagostera 
M, Valero C, Bayona X, et al. Factors associated 
with changes in quality of life of COPD patients: 
a prospective study in primary care. Respir 
Med. 2013; 107 (10): 1589-97. DOI 10.1016/j.
rmed.2013.05.009
13. Pineda-Higuita SE, Ramos-Melchor VJ, Cadavid-
Carmona D. Calidad de vida en pacientes con 
Enfermedad Pulmonar Obstructiva.  Univ 
Salud. 2016;  18 (3): 482-93. DOI 10.22267/
rus.161803.53
14. Crisafulli E, Costi S, Luppi F, Cirelli G, Cilione C, 
Coletti O, et al. Role of comorbidities in a cohort 
of patients with COPD undergoing pulmonary 
rehabilitation. Thorax. 2008; 63 (6): 487-92. DOI 
10.1136/thx.2007.086371
15. García-Olmos L, Alberquilla Á, Ayala V, 
García-Sagredo P, Morales L, Carmona M, et al. 
Comorbidity in patients with chronic obstructive 
pulmonary disease in family practice: a cross 
sectional study. BMC Fam Pract. 2013; 14 (1): 11. 
DOI 10.1186/1471-2296-14-11
16. Battaglia S, Basile M, Scichilone N, Bellia V. 
Prevalence of co-morbidities and severity 
of COPD.  COPD. 2015;  12 (4): 390-4. DOI 
10.3109/15412555.2014.974734
17. Putcha N, Puhan MA, Hansel NN, Drummond 
MB, Boyd CM. Impact of co-morbidities on self-
rated health in self-reported COPD: an analysis 
of NHANES 2001–2008.  COPD. 2013;  10 (3): 
324-32. DOI 10.3109/15412555.2012.744963
Prevalence of comorbidity in patients with lung disease
280 Duazary: Revista Internacional de Ciencias de la Salud / ISSN: 1794-5992 / Vol. 15, No. 3, septiembre - diciembre de 2018
DOI: http://dx.doi.org/10.21676/2389783X.2418
18. Koskela J, Kilpeläinen M, Kupiainen H, Mazur 
W, Sintonen H, Boezen M, et al. Co-morbidities 
are the key nominators of the health 
related quality of life in mild and moderate 
COPD. BMC Pulm Med. 2014; 14 (1): 102. DOI 
10.1186/1471-2466-14-102
19. Divo MJ, Casanova C, Marin JM, Pinto-Plata 
VM, de-Torres JP, Zulueta JJ, et al. COPD 
comorbidities network.  Eur Respir J. 2015;  46 
(3): 640-50. DOI 10.1183/09031936.00171614
20. Huber MB, Wacker ME, Vogelmeier CF, Leidl R. 
Comorbid influences on generic health-related 
quality of life in COPD: a systematic review. PloS 
One. 2015;  10 (7): e0132670.DOI 10.1371/
journal.pone.0132670
21. Katz MH. Multivariable analysis. Second edition. 
Cambridge: Cambridge University Press; 2006.
22. Global Initiative for Chronic Obstructive Lung 
Disease. GOLD 2017. Global strategy for the 
diagnosis, management and Prevent of chronic 
obstructive pulmonary disease, updated 2014. 
Disponible en: http://www.goldcopd.org (Fecha 
de acceso: 01-05-2017).
23. Miller MR, Hankinson J, Brusasco V, Burgos F, 
Casaburi R, Coates A, et al. Standardisation of 
spirometry. Euro Respir J. 2005; 26 (2): 319-38. 
DOI 10.1183/09031936.05.00034805
24. Sorino C, Battaglia S, Scichilone N, Pedone 
C, Antonelli-Incalzi R, Sherrill D, et al. 
Diagnosis of airway obstruction in the elderly: 
contribution of the SARA study. Inter J Chron 
Obstruct Pulmon Dis. 2012; 7: 389-95. DOI 
10.2147/COPD.S31630
25. Jones PW, Harding G, Berry P, Wiklund I, 
Chen WH, Leidy NK. Development and 
first validation of the COPD Assessment 
Test.  Eur Respir J. 2009;  34 (3): 648-54. DOI 
10.1183/09031936.00102509
26. Gupta N, Pinto LM, Morogan A, Bourbeau 
J. The COPD assessment test: a systematic 
review. Eur Respir J. 2014; 44 (4): 873-84. DOI 
10.1183/09031936.00025214
27. IBM-SPSS Statistics for Windows, version 22.0. 
Armonk: SPSS. Inc.; 2013.
28. Resolución 008430 por la cual se establecen las 
normas científicas, técnicas y administrativas 
para la investigación en salud. Bogotá: Ministerio 
de Salud de Colombia; 1993.
29. Mesa SB, Restrepo DA. Conceptos esenciales 
de la EPOC, prevalencia e impacto en América 
Latina. Medicina UPB. 2015; 34 (1):49-60.
30. Cavaillès A, Brinchault-Rabin G, Dixmier A, 
Goupil F, Gut-Gobert C, Marchand-Adam S, et al. 
Comorbidities of COPD. Eur Respir Rev. 2013; 22 
(130): 454-75. DOI 10.1183/09059180.00008612
31. van der Molen T. Co-morbidities of COPD in 
primary care: frequency, relation to COPD, 
and treatment consequences.  Prim Care 
Respir J. 2005;  19(4): 326-34. DOI 10.4104/
pcrj.2010.00053
32. Shapiro S. Causation, bias and confounding: a 
hitchhiker’s guide to the epidemiological galaxy. J 
Fam Plann Reprod Health Care. 2008;34(4): 
261-4.
33. Fosgate GT. Practical sample size calculations for 
surveillance and diagnostic investigations. J Vet 
Diag Invest. 2009; 21(1):3-14.
